- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of combining radiotherapy with immune-checkpoint inhibition
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 15, Issue 8, Pages 477-494
Publisher
Springer Nature
Online
2018-06-05
DOI
10.1038/s41571-018-0046-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
- (2018) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- A single-arm, phase II study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).
- (2018) Heather L. McArthur et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects
- (2018) Kevin Diao et al. JOURNAL OF NEUROSURGERY
- Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation
- (2018) Allison M. Martin et al. JAMA Oncology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
- (2018) William L. Hwang et al. JAMA Oncology
- Partial Tumor Irradiation in a Murine Model is Sufficient for Tumor Control via Activation of an Antitumor Immune Response
- (2017) R. Samstein et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
- (2017) Noelle L. Williams et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
- (2017) Andrew Bang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015
- (2017) Lucie M. Turcotte et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis
- (2017) Ibiayi Dagogo-Jack et al. JOURNAL OF IMMUNOTHERAPY
- Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma
- (2017) Penny Fang et al. JOURNAL OF NEURO-ONCOLOGY
- Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors
- (2017) Sophie Feng et al. Journal of Thoracic Oncology
- The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)
- (2017) Nickhill Bhakta et al. LANCET
- HPV-related oropharyngeal carcinoma de-escalation protocols
- (2017) Ricard Mesía et al. LANCET ONCOLOGY
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy
- (2017) Amélie Aboudaram et al. MELANOMA RESEARCH
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent Developments in Radiotherapy
- (2017) Deborah E. Citrin NEW ENGLAND JOURNAL OF MEDICINE
- Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation
- (2017) Luke R.G. Pike et al. RADIOTHERAPY AND ONCOLOGY
- Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
- (2017) Laura C. Cappelli et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Pelvic Radiation and Normal Tissue Toxicity
- (2017) Sarah Nicholas et al. SEMINARS IN RADIATION ONCOLOGY
- Management of Radiation Toxicity in Head and Neck Cancers
- (2017) Farzan Siddiqui et al. SEMINARS IN RADIATION ONCOLOGY
- Radiation-Induced Liver Toxicity
- (2017) Pablo Munoz-Schuffenegger et al. SEMINARS IN RADIATION ONCOLOGY
- Thoracic Radiation Normal Tissue Injury
- (2017) Charles B. Simone SEMINARS IN RADIATION ONCOLOGY
- Mechanisms of Normal Tissue Injury From Irradiation
- (2017) Deborah E. Citrin et al. SEMINARS IN RADIATION ONCOLOGY
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab
- (2017) Tijana Skrepnik et al. OncoImmunology
- Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
- (2016) Vishwajith Sridharan et al. BRITISH JOURNAL OF CANCER
- Systematic review of case reports on the abscopal effect
- (2016) Yazan Abuodeh et al. CURRENT PROBLEMS IN CANCER
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Use of LDH and autoimmune side effects to predict response to ipilimumab treatment
- (2016) J Dick et al. Immunotherapy
- Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis
- (2016) Jacob A. Miller et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab
- (2016) Rosie Qin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
- (2016) Rovel J. Colaco et al. JOURNAL OF NEUROSURGERY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Radiotherapy in patients with connective tissue diseases
- (2016) Niccolò Giaj-Levra et al. LANCET ONCOLOGY
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
- (2016) Michael B. Bernstein et al. Nature Reviews Clinical Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Lymphocytes in Radiotherapy-Induced Adverse Late Effects in the Lung
- (2016) Florian Wirsdörfer et al. Frontiers in Immunology
- Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
- (2016) E. Liniker et al. OncoImmunology
- Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer
- (2016) Neige M. Y. Journy et al. JAMA Oncology
- Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients
- (2016) Vishwajith Sridharan et al. Journal for ImmunoTherapy of Cancer
- Immunological markers that predict radiation toxicity
- (2015) Carl N. Sprung et al. CANCER LETTERS
- The effect of ionizing radiation on regulatory T cells in health and disease
- (2015) Eszter Persa et al. CANCER LETTERS
- Predictors of radiation therapy (RT) use among Medicare patients with metastatic non-small cell lung cancer (NSCLC).
- (2015) Miranda Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases
- (2015) Zachary A. Kohutek et al. JOURNAL OF NEURO-ONCOLOGY
- Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer
- (2015) Matthew Koshy et al. JNCI-Journal of the National Cancer Institute
- Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer
- (2015) Nami Ueki et al. Journal of Thoracic Oncology
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
- (2015) Andrew B Sharabi et al. LANCET ONCOLOGY
- Delayed brain radiation necrosis: pathological review and new molecular targets for treatment
- (2015) Motomasa Furuse et al. Medical Molecular Morphology
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
- (2015) Michael Schaapveld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer
- (2015) Matthew Koshy et al. JNCI-Journal of the National Cancer Institute
- Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review
- (2015) Jonathan D. Schoenfeld et al. Journal for ImmunoTherapy of Cancer
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation
- (2014) Kate S. Smigiel et al. IMMUNOLOGICAL REVIEWS
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Comparison of Local Recurrence With Conventional and Intensity-Modulated Radiation Therapy for Primary Soft-Tissue Sarcomas of the Extremity
- (2014) Michael R. Folkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity
- (2014) James B. Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist
- (2014) Miguel R Ferreira et al. LANCET ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012
- (2014) Michael B. Barton et al. RADIOTHERAPY AND ONCOLOGY
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response
- (2013) Michel DuPage et al. CURRENT OPINION IN IMMUNOLOGY
- Radiation and immunotherapy: a synergistic combination
- (2013) Anusha Kalbasi et al. JOURNAL OF CLINICAL INVESTIGATION
- Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
- (2013) Silvia C. Formenti et al. JNCI-Journal of the National Cancer Institute
- Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: The potential risk of extensive radiation pneumonitis
- (2013) Shinsaku Yamaguchi et al. LUNG CANCER
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies
- (2013) Nishant Verma et al. NEURO-ONCOLOGY
- Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
- (2013) C. A. Barker et al. Cancer Immunology Research
- T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
- (2012) A. Facciabene et al. CANCER RESEARCH
- Optimizing Cancer Treatments to Induce an Acute Immune Response: Radiation Abscopal Effects, PAMPs, and DAMPs
- (2012) C. M. Ludgate CLINICAL CANCER RESEARCH
- The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells
- (2012) Andrea Balogh et al. INFLAMMATION RESEARCH
- Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
- (2012) A. Gupta et al. JOURNAL OF IMMUNOLOGY
- Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity
- (2012) James B. Yu et al. JNCI-Journal of the National Cancer Institute
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
- (2012) Anna Maria Di Giacomo et al. LANCET ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokines in Radiobiological Responses: A Review
- (2012) Dörthe Schaue et al. RADIATION RESEARCH
- Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries
- (2011) Amy Berrington de Gonzalez et al. LANCET ONCOLOGY
- Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
- (2011) Christopher M Nutting et al. LANCET ONCOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of Brain Metastases
- (2011) Lakshmi Nayak et al. Current Oncology Reports
- MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer
- (2010) A. Choudhury et al. CANCER RESEARCH
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- Radiation Enhances Regulatory T Cell Representation
- (2010) Evelyn L. Kachikwu et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Chronic Radiation Enteritis
- (2009) V.S. Theis et al. CLINICAL ONCOLOGY
- Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases
- (2009) Mercedes Fernández-Mestre et al. HUMAN IMMUNOLOGY
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CNS complications of radiotherapy and chemotherapy
- (2009) Carole Soussain et al. LANCET
- Graft-versus-host disease
- (2009) James LM Ferrara et al. LANCET
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Autophagy is required during cycling hypoxia to lower production of reactive oxygen species
- (2009) Kasper M.A. Rouschop et al. RADIOTHERAPY AND ONCOLOGY
- Systemic Lupus Erythematosus, Radiotherapy, and the Risk of Acute and Chronic Toxicity: The Mayo Clinic Experience
- (2008) Melva E. Pinn et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started